Attending physicians' and residents' attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital

Family Medicine

Volumn 38, Issue 5, 2006, Pages 336-340

  Cunningham, Chinazo O ^a   Sohler, Nancy L ^a,b   McCoy, Kate ^a   Kunins, Hillary V ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; OPIATE;

ADULT; AMBULATORY CARE; ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE TREATMENT; FEMALE; HUMAN; HUMAN EXPERIMENT; INTERVIEW; MALE; OPIATE ADDICTION; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIMARY MEDICAL CARE; QUESTIONNAIRE; RESIDENT; TEACHING HOSPITAL; URBAN AREA;

ADULT; ATTITUDE OF HEALTH PERSONNEL; BUPRENORPHINE; CROSS-SECTIONAL STUDIES; FEMALE; HOSPITALS, TEACHING; HUMANS; INTERNSHIP AND RESIDENCY; MALE; NARCOTIC ANTAGONISTS; NARCOTICS; PHYSICIANS; PRESCRIPTIONS, DRUG; SUBSTANCE-RELATED DISORDERS;

EID: 33646561547     PISSN: 07423225     EISSN: 07423225     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Crane E. Narcotic analgesics. The Drug Abuse Warning Network (DAWN) Report. 2003. Available at http://oas.samhsa.gov/2k3/pain/DAWNpain.pdf. Accessed July 18, 2005.
2. Office of National Drug Control Policy (ONDCP). Drug Policy Information Clearinghouse. Heroin fact sheet. 2003. Available at www.whitehousedrugpolicy. gov/publications/factsht/heroin/197335.pdf. Accessed July 15, 2005.
3. Substance Abuse and Mental Health Services Administration Office of Applied Studies. Emergency department trends from the Drug Abuse Warning Network, final estimates 1995-2002. DAWN Series: D-24, DHHS Publication No. (SMA) 03-3780. Rockville, Md: Department of Health and Human Services, 2003. Available at http://dawninfo.samhsa.gov/old_dawn/pubs_94_02/edpubs/2002final/ files/EDTrendFinal02AllText.pdf. Accessed July 15, 2005.
4. Kakko J, Svanborg KD, Kreek MJ, Heilig M. One-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003;361(9358):662-8.
5. Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA 1998;280(22):1936-43.
6. Ball JC, Ross A. The effectiveness of methadone maintenance treatment: patients, programs, services, and outcome. New York: Springer-Verlag, 1991.
7. Fiellin DA, O'Connor PG. Clinical practice. Office-based treatment of opioid-dependent patients. N Engl J Med 2002;347(11):817-23.
8. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual tablet formulation of buprenorphine and naloxone. N Engl J Med 2003;349(10):949-58.
9. Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance versus 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 2000;283(10):1303-10.
10. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000;343(18):1290-7.
11. O'Connor PG, Fiellin DA. Pharmacologic treatment of heroin-dependent patients. Ann Intern Med 2000;133(1):40-54.
12. Office of National Drug Control Policy. Executive Office of the President, Office of National Drug Control Policy. Consultation document on opioid agonist treatment. September 3, 2003. Available at www. whitehousedrugpolicy.gov/science_tech/methadone/contents.html. Accessed on July 15, 2005.
13. Fiellin DA, O'Connor PG. New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med 2002;137(8):688-92.
14. Fiellin DA, Pantalon MV, Pakes JP, O'Connor PG, Chawarski M, Schottenfeld RS. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse 2002;28(2):231-41.
15. Gibson AE, Doran CM, Bell JR, Ryan A, Lintzeris N. A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial. Med J Aust 2003;179(1):38-42.
16. O'Connor PG, Oliveto AH, Shi JM, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med 1998;105(2):100-5.
17. O'Connor PG, Oliveto AH, Shi JM, et al. A pilot study of primary care-based buprenorphine maintenance for heroin dependence. Am J Drug Alcohol Abuse 1996;22(4):523-31.
18. McNeely J, Drucker E, Hartel D, Tuchman E. Office-based methadone prescribing: acceptance by inner-city practitioners in New York. J Urban Health 2000;77(1):96-102.
19. Turner BJ, Laine C, Lin YT, Lynch K. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med 2005;165(15):1769-76.
20. Raisch DW, Fudala PJ, Saxon AJ, et al. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/naloxone to patients with opioid dependence. J Am Pharm Assoc (Washington, DC) 2005;45(1):23-32.
21. West JC, Kosten TR, Wilk J, et al. Challenges in increasing access to buprenorphine treatment for opiate addiction. Am J Addict 2004;13 Suppl 1:S8-S16.